Prostate adenocarcinoma (PRAD) is one of the most frequently diagnosed cancer in males. Previous studies had demonstrated long non-coding RNAs (lncRNAs) played crucial roles in human cancers. In present study, we reported ten disease-free survival time related lncRNAs in PRAD, including RP11-468E2.5, GS1-393G12.13, CTD-2228K2.7, RP11-783K16.13, RP11-631N16.4, CTC-435M10.12, RP11-1109F11.5, RP11-228B15.4, RP11-496I9.1, and RP11-95O2.5. Higher expression of these lncRNAs significantly correlates to shorter DFS time in patients with PRAD. We next constructed lncRNAs regulating PPI networks in PRAD. Bioinformatics analysis revealed these DFS-related lncRNAs were associated with the regulation of cell cycle, glucose metabolic process, histone modification, and RNA splicing. AR and SPOP were identified to be involved in regulating these lncRNAs expression in PRAD. The prognostic value and molecular functions of these lnRNAs in human diseases remained largely unknown. We thought this study for the first time demonstrated that they could act as novel potential biomarkers for PRAD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3934/mbe.2020108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metastatic Prostatic Adenocarcinoma With Paneth Cell-Like Neuroendocrine Differentiation.
Mayo Clin Proc
January 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Introduction: Prostate cancer is incidentally diagnosed in 6%-11% of benign prostatic hyperplasia surgeries.
Case Presentation: A 79-year-old man was diagnosed with benign prostatic hyperplasia. The prostate volume was 54.
Not all stains are made equal: impact of stain normalization on prostate cancer diagnosis.
Pathologica
October 2024
Biolab, PoliToBIOMed Lab, Department of Electronics and Telecommunications, Politecnico di Torino, Turin, Italy.
Objective: Stain normalization is a technique used to standardize the color appearance of digital whole slide images (WSIs). This study aimed to assess the impact of digital stain normalization on prostate cancer diagnosis by pathologists.
Methods: A multi-institutional board of four pathologists evaluated 407 hematoxylin and eosin (H&E) prostate WSIs before and after stain normalization.
Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.
Prostate
January 2025
Department of Medical Oncology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
Background: The Nectin-4 directed antibody drug conjugate enfortumab vedotin (EV) has emerged as frontline systemic therapy in combination with immune checkpoint blockade for urothelial carcinoma (UC), capitalizing on the ubiquitous expression of this protein in UC. There is limited data available regarding expression of Nectin-4 by immunohistochemistry in prostate cancer, but this is of interest as a substantial number of UC patients likely to receive EV have concomitant prostate cancer.
Methods: Nectin-4 protein expression was evaluated by immunohistochemistry in tissue microarrays encompassing a cohort of 302 prostatic adenocarcinomas spanning Grade Groups 1-5.
Dose Recommendations for Prostrate-specific Membrane Antigen Positron Emission Tomography (PSMA PET) Guided Boost Irradiation to Lymphatic Tissue in Prostate Adenocarcinoma.
Clin Oncol (R Coll Radiol)
December 2024
Alberta Health Services, South Zone, Lethbridge, AB, Canada; University of Calgary, Department of Oncology, Calgary, AB, Canada; University of Calgary, Department of Physics and Astronomy, Calgary, AB, Canada.
Aims: Prostrate-specific membrane antigen positron emission tomography (PSMA-PET) imaging has led to an increase in identifiable small volume metastatic disease in prostate adenocarcinoma. There is clinical equipoise in how to treat these using radiotherapy regimens. The aim of this study is to determine an adequate dosing regimen for small volume lymphatic metastases in prostate adenocarcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!